University of Hertfordshire

Microvesicles and epithelial mesenchymal transition in the development of cancer

Research output: Contribution to conferencePosterpeer-review

Standard

Microvesicles and epithelial mesenchymal transition in the development of cancer. / Inal, Jameel.

2012. Poster session presented at Microvesiculation and Disease, a Biochemical Society Focused Meeting, London, United Kingdom.

Research output: Contribution to conferencePosterpeer-review

Harvard

Inal, J 2012, 'Microvesicles and epithelial mesenchymal transition in the development of cancer', Microvesiculation and Disease, a Biochemical Society Focused Meeting, London, United Kingdom, 13/09/12 - 14/09/12.

APA

Inal, J. (2012). Microvesicles and epithelial mesenchymal transition in the development of cancer. Poster session presented at Microvesiculation and Disease, a Biochemical Society Focused Meeting, London, United Kingdom.

Vancouver

Inal J. Microvesicles and epithelial mesenchymal transition in the development of cancer. 2012. Poster session presented at Microvesiculation and Disease, a Biochemical Society Focused Meeting, London, United Kingdom.

Author

Inal, Jameel. / Microvesicles and epithelial mesenchymal transition in the development of cancer. Poster session presented at Microvesiculation and Disease, a Biochemical Society Focused Meeting, London, United Kingdom.

Bibtex

@conference{2789929e6149431ea4c0f0cd1d5ce6ac,
title = "Microvesicles and epithelial mesenchymal transition in the development of cancer",
abstract = "Microvesicles released by tumour cell lines are thought to play an important role in both extracellular matrix (ECM) invasion and evasion of the immune system. We have examined the role of MVs derived from a T cell line (Jurkat) on PNT2 cells (normal prostate cells) to see if they carry some bioactive molecules capable of inducing an epithelial to mesenchymal transition (EMT) in normal prostate cells. The link between EMT and malignancy has been well documented in almost all carcinomas of epithelial origin. However, to understand the mechanism by which MVs may induce this and to show the factors carried by MVs, further tests including invasion assays, angiogenesis and apoptotic assays as well as proteomic analyses will be needed. By microscopic analysis, PNT2 cells, which are of epithelial origin, treated with Jurkat MVs, showed some morphological changes. They become elongated, motile and morphologically mesenchymal-like as previously documented. The molecular changes were confirmed by immunohistochemical techniques using the fluorescencent microscope and flow cytometer. The experimental (MV-treated cells) compared to control (untreated cells) expressed high level of mesenchymal markers such as Vimentin and low levels of epithelial markers such as E-Cadherin. Proteins from PNT2 control cells and MV- treated cells were profiled by SDS- PAGE, MV-treated cells showing a band around 13 kDa. To identify this protein we intend to sequence it using mass spectrometry. ",
author = "Jameel Inal",
year = "2012",
month = sep,
day = "13",
language = "English",
note = "Microvesiculation and Disease, a Biochemical Society Focused Meeting : Microvesiculation and Disease ; Conference date: 13-09-2012 Through 14-09-2012",
url = "https://www.biochemistry.org/Events/tabid/379/View/programme/MeetingNo/SA133/Default.aspx",

}

RIS

TY - CONF

T1 - Microvesicles and epithelial mesenchymal transition in the development of cancer

AU - Inal, Jameel

PY - 2012/9/13

Y1 - 2012/9/13

N2 - Microvesicles released by tumour cell lines are thought to play an important role in both extracellular matrix (ECM) invasion and evasion of the immune system. We have examined the role of MVs derived from a T cell line (Jurkat) on PNT2 cells (normal prostate cells) to see if they carry some bioactive molecules capable of inducing an epithelial to mesenchymal transition (EMT) in normal prostate cells. The link between EMT and malignancy has been well documented in almost all carcinomas of epithelial origin. However, to understand the mechanism by which MVs may induce this and to show the factors carried by MVs, further tests including invasion assays, angiogenesis and apoptotic assays as well as proteomic analyses will be needed. By microscopic analysis, PNT2 cells, which are of epithelial origin, treated with Jurkat MVs, showed some morphological changes. They become elongated, motile and morphologically mesenchymal-like as previously documented. The molecular changes were confirmed by immunohistochemical techniques using the fluorescencent microscope and flow cytometer. The experimental (MV-treated cells) compared to control (untreated cells) expressed high level of mesenchymal markers such as Vimentin and low levels of epithelial markers such as E-Cadherin. Proteins from PNT2 control cells and MV- treated cells were profiled by SDS- PAGE, MV-treated cells showing a band around 13 kDa. To identify this protein we intend to sequence it using mass spectrometry.

AB - Microvesicles released by tumour cell lines are thought to play an important role in both extracellular matrix (ECM) invasion and evasion of the immune system. We have examined the role of MVs derived from a T cell line (Jurkat) on PNT2 cells (normal prostate cells) to see if they carry some bioactive molecules capable of inducing an epithelial to mesenchymal transition (EMT) in normal prostate cells. The link between EMT and malignancy has been well documented in almost all carcinomas of epithelial origin. However, to understand the mechanism by which MVs may induce this and to show the factors carried by MVs, further tests including invasion assays, angiogenesis and apoptotic assays as well as proteomic analyses will be needed. By microscopic analysis, PNT2 cells, which are of epithelial origin, treated with Jurkat MVs, showed some morphological changes. They become elongated, motile and morphologically mesenchymal-like as previously documented. The molecular changes were confirmed by immunohistochemical techniques using the fluorescencent microscope and flow cytometer. The experimental (MV-treated cells) compared to control (untreated cells) expressed high level of mesenchymal markers such as Vimentin and low levels of epithelial markers such as E-Cadherin. Proteins from PNT2 control cells and MV- treated cells were profiled by SDS- PAGE, MV-treated cells showing a band around 13 kDa. To identify this protein we intend to sequence it using mass spectrometry.

M3 - Poster

T2 - Microvesiculation and Disease, a Biochemical Society Focused Meeting

Y2 - 13 September 2012 through 14 September 2012

ER -